Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Tel Aviv, Israel
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver. Further details of the presented data will be forthcoming.
"Our poster presentations at EULAR and EASL highlight the novelty and potential of our unique approach to fibro-inflammatory diseases," said Dale Pfost, PhD, CEO of Chemomab. "The presentations encompass some of our extensive preclinical work on CCL24, whose dual activity in driving the fibro-inflammatory vicious cycle makes it a promising target for poorly-treated diseases including primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The presentations also provide details of our clinical programs in PSC and SSc, as well as clinical data from our Phase 2 liver fibrosis trial in NASH patients, including some encouraging new data from recently completed analyses. We also are pleased that our data are being presented by respected opinion leaders who continue to be supportive of the clinical development of CM-101, our first-in-class therapy that targets both inflammation and fibrosis."
EULAR23 – European Congress of Rheumatology – Milan, Italy, May 31-June 3, 2023
| Date: | June 2, 2023 |
| Time: | 14:45-15:45 CEST |
| Format: | Poster presentation: CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis |
| Presenter: | Professor Enrico De Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal Diseases, University of Leeds, UK |
| Session: | Poster Hall |
| Information: | https://congress.eular.org/ |
EASL Congress 2023 – Vienna, Austria, June 21-24, 2023
| Date: | June 21 - 24, 2023 |
| Time: | 9-17:00 CEST every day |
| Format: | Poster presentation: Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: A proof-of-concept study |
| Presenter: | Professor Rifaat Safadi, Professor in Medicine, Gastroenterology and Hepatology, Faculty of Medicine, Hadassah University Hospital, Jerusalem, Israel and visiting Scholar, Division of Liver Diseases, Mount Sinai School of Medicine, New York City, USA |
| Session: | Poster-Late-Breaker, LBP-28 |
| Information: | https://congress-easl.com/ |
EASL Congress 2023 – Vienna, Austria, June 21-24, 2023
| Date: | June 22, 2023 |
| Time: | 9:00-18:30 CEST |
| Format: | Poster presentation: Targeting CCL24 in primary sclerosing cholangitis with CM-101: rationale and study design |
| Presenter: | Professor Douglas Thorburn, Divisional Clinical Director for Liver and Digestive Health and Professor of Hepatology , University College London, UK |
| Session: | Rare Liver Diseases, Abstract #303 |
| Information: | https://congress-easl.com/ |
EASL Congress 2023 – Vienna, Austria, June 21-24, 2023
| Date: | June 23, 2023 |
| Time: | 9:00-18:00 CEST |
| Format: | Poster presentation: Serum proteomics reveals association of CCL24 with key aspects of primary sclerosing cholangitis |
| Presenter: | Revital Aricha, PhD, Vice President, Translational Science, Chemomab |
| Session: | Immune-mediated and cholestatic: Experimental and pathophysiology, Abstract #2178 |
| Information: | https://congress-easl.com/ |
In addition, Chemomab's corporate development team will be in Boston June 5-8, 2023, participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.
English
Deutsch
Nederlands